Anticoagulant Therapy for Venous Thromboembolism in Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

1. Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
   Pooled it
2. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.Journal of blood medicine · 2024
   Review
3. Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis.Cancers · 2023
   Review
4. Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.Reviews in cardiovascular medicine · 2023
   Review
5. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.Current oncology reports · 2023
   Review
6. Venous thrombosis, multiple carcinomatous foci and differences in metastatic pathways of penile carcinoma.Oncology letters · 2023
   Article
7. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients.Experimental hematology & oncology · 2022
   Review
8. The prognostic role of extended preoperative hypercoagulability work-up in high-risk microsurgical free flaps: a single-center retrospective case series of patients with heterozygotic factor V Leiden thrombophilia.BMC surgery · 2022
   Article
9. Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022
   Review
10. The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature.Medicina (Kaunas, Lithuania) · 2021
    Review
11. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.JAMA network open · 2021
    Article
12. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.Blood advances · 2020
    Article
13. Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review

Corrections and comments

• Comment on
  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.2020

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as